Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit?
NCT01431859 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2016-04-06
Summary
Birch pollen allergy is increasingly common. It causes asthma and early season hay fever. This is because the body recognises birch pollen and reacts to it, leading to symptoms. Many patients with birch allergy get an itchy and/or swollen mouth when they eat fresh fruit (apples, pears, peaches, plums etc). Some fruit proteins have a similar structure to birch pollen; because of this the body recognises these proteins too causing the immune system to respond. This response causes symptoms of itch and swelling inside the mouth and throat. the investigators want to find out whether it is possible to get rid of the fruit-induced symptoms by using a desensitisation procedure that has been developed for treating the kind of hay fever that is caused by birch pollen. Desensitisation involves giving a small injection of pollen just under the skin and gradually increasing the amount each week. This allows the body to build up a "tolerance" to the injected protein. When the pollen is then encountered in real life the immune system reacts less vigorously so symptoms are less severe. This treatment does reduce hay fever symptoms. Our study aims to find out if this tolerance is transferred to the fruit proteins enabling patients to eat apples with minimal symptoms. Patients will be given apple to eat in a hidden form before treatment and their response assessed. They will then receive either active or dummy pollen injections before birch pollen season. A few months after completing these injections they will have another disguised apple test to see whether their symptoms are any better. If symptoms have improved with treatment then this therapy could be offered to patients in the future. This would allow them to eat fresh fruit without worrying about unpleasant symptoms and improve their hay fever symptoms.
Conditions
- Oral Allergy Syndrome
Interventions
- BIOLOGICAL
-
Allergovit Birch pollen
Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
- OTHER
-
Placebo
Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
Sponsors & Collaborators
-
Royal Sussex County Hospital
lead OTHER
Principal Investigators
-
Anthony Frew, MBBS MD FRCP · Brighton and Sussex University Hospital Trust
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-07-31
- Primary Completion
- 2016-11-30
- Completion
- 2016-11-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
NCT00310466 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Safety Study of a Birch Pollen Allergen Extract
NCT00818181 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen
NCT01728519 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
NCT00263627 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
NCT01731249 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
NCT00309062 ·Status: COMPLETED ·Phase: PHASE3
-
Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen
NCT01719133 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber
NCT04583202 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis
NCT03157505 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Validation of Birch Pollen in the EEU
NCT02351830 ·Status: COMPLETED ·Phase: NA
-
Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC
NCT02271009 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
NCT05668390 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
NCT00410930 ·Status: TERMINATED ·Phase: PHASE2
-
Mechanisms of Allergen Immunotherapy
NCT01523158 ·Status: TERMINATED ·Phase: NA
-
Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.
NCT04622917 ·Status: COMPLETED ·Phase: PHASE4
-
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
NCT01144429 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
NCT01720251 ·Status: COMPLETED ·Phase: PHASE2
-
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
NCT04912076 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
NCT07155499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Nasal Allergen Challenge Test as a Method to Detect Clinical Reactivity Against Birch Pollen
NCT06085963 ·Status: COMPLETED ·Phase: NA
-
A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
NCT04878354 ·Status: COMPLETED ·Phase: PHASE3
-
Study of DM-101PX in Adults With Birch Pollen Allergy
NCT07254871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SUBLIVAC FIX Birch Phase III Short-term Efficacy
NCT02231307 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC
NCT04641130 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure Chamber
NCT06267261 ·Status: COMPLETED ·Phase: NA